Craig Fox
Chief Tech/Sci/R&D Officer chez C4X Discovery Ltd.
Profil
Craig Fox is currently the Director & Chief Scientific Officer at C4X Discovery Ltd.
and an Operating Partner at Oxford Science Enterprises PLC.
Previously, he was the Chief Scientific Officer & Executive Director at C4X Discovery Holdings Plc from 2016 to 2022 and the Director-Respiratory Research at Pulmagen Therapeutics LLP.
He holds a doctorate from the University of Birmingham and an undergraduate degree from the University of Surrey.
Postes actifs de Craig Fox
| Sociétés | Poste | Début |
|---|---|---|
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Private Equity Investor | 01/02/2022 |
Anciens postes connus de Craig Fox
| Sociétés | Poste | Fin |
|---|---|---|
| C4X DISCOVERY HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 31/03/2022 |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Corporate Officer/Principal | 01/01/2010 |
Formation de Craig Fox
| University of Birmingham | Doctorate Degree |
| University of Surrey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| C4X DISCOVERY HOLDINGS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |
